ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2019.7407 ETM-0-0-7407 Articles Predictive value of P-selectin and endothelin-1 for vascular restenosis after interventional procedures for peripheral artery disease ChenNan ChenLinwei JiangSu WangZichuan LiuTao Department of Science of Epidemic Febrile Disease, School of Basic Medical Sciences, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China Correspondence to: Dr Tao Liu, Department of Science of Epidemic Febrile Disease, School of Basic Medical Sciences, Nanjing University of Chinese Medicine, 138 Xianlin Street, Nanjing, Jiangsu 210023, P.R. China, E-mail: liutnucm@163.com 05 2019 18 03 2019 17 5 3907 3912 28062018 22012019 Copyright: © Chen et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Peripheral artery disease (PAD) is caused by the building up of plaques in the arteries that carry blood to the lower limbs. The present study aimed to assess the predictive value of the plasma levels of P-selectin (Ps) or endothelin-1 (ET-1) regarding the occurrence of vascular restenosis after endovascular therapy for PAD. Patients with or without vascular restenosis confirmed by computed tomography angiography after endovascular therapy between March and December 2015 (n=20 per group) were enrolled. The serum levels of Ps and ET-1 prior to the operation and at 1 h, as well as 1, 2 and 3 weeks after the operation were compared between the two groups. At 1 h after the operation, the serum levels of Ps and ET-1 were significantly increased as compared with the pre-operative levels (P<0.05). The serum levels of Ps and ET-1 at 1 h, as well as 1, 2 and 3 weeks after the operation in the restenosis group were significantly higher as compared with those in the non-stenosis group (P<0.05). However, for the non-stenosis group, the serum levels of Ps and ET-1 at 1, 2 and 3 weeks after the operation did not significantly differ from the pre-operative levels (P>0.05). The diagnostic sensitivity and specificity of the serum ET-1 levels at 1 h after the operation for predicting post-operative restenosis in PAD patients with a cut-off of 0.1089 pg/ml were 85 and 85%, respectively. In conclusion, the serum levels of Ps and ET-1 have a high predictive value for post-operative vascular restenosis after endovascular therapy for PAD patients.

 peripheral artery disease P-selectin endothelin-1 vascular restenosis Introduction

Peripheral artery disease (PAD) is caused by the formation of atherosclerotic plaques in the lower extremities, resulting in arterial stenosis and occlusion to finally lead to chronic ischemia of the extremities. Epidemiological surveys have indicated that PAD is positively correlated with age, and hypertension, hyperlipidemia, smoking and a family history of PAD are all risk factors for PAD (1,2). In China, the incidence of patients with PAD and arteriosclerosis obliterans of the lower extremities is increasing annually, and this is attributed o an aging population due to improved medical care and overall living standards (3). Minimally invasive endovascular therapies, including stent placement (4) and percutaneous transluminal angioplasty (PTA) (5), provide a safer and more reliable treatment for PAD. However, these therapies may cause damage to the vascular intima, leading to post-operative vascular restenosis (6). Furthermore, interventional procedures severely affect post-operative recovery and the quality of life of elderly PAD patients (7). Therefore, early prediction and treatment of post-operative vascular restenosis in PAD patients may greatly improve their prognosis (8). P-selectin (Ps) (9) and endothelin-1 (ET-1) (10) are important proteins that reflect the damage, activation and synthesis of vascular endothelial cells (VECs). In the present study, the serum levels of Ps and ET-1 were monitored in PAD patients after endovascular therapy and their correlation with post-operative vascular restenosis was assessed in order to determine their early predictive value regarding this adverse event.

 Patients and methods <sec> <title>Patients

A total of 20 PAD cases with restenosis and another 20 PAD cases or without restenosis after endovascular therapy were enrolled in the present study between March 2015 and December 2015 from Taizhou Hospital Affiliated to Nanjing University of Chinese Medicine. The restenosis and non-restenosis groups were comparable in age, sex, incidence of concurrent hypertension or hyperlipidemia, location of the lesion, Rutherford classification and family history of PAD (P>0.05). The demographic and clinicopathological characteristics of the subjects at baseline are presented in Table I. All patients provided written informed consent. All of the experiments were approved by the Ethics Committee of Nanjing University of Chinese Medicine (Nanjing, China).

 Diagnostic methods and comparisons

Restenosis was diagnosed by post-operative examination using computed tomography angiography (CTA). Cases with and without restenosis were compared regarding age, sex, incidence of concurrent hypertension or hyperlipidemia, location of the lesion, Rutherford classification, family history of diseases and smoking status. The serum levels of Ps and ET-1 prior to the operation and at 1 h, 1, 2 and 3 weeks after the operation were compared within and between groups.

 Processing and detection of blood samples

From each subject, 5 ml blood was drawn on the morning prior to the operation and at 1 h, 1, 2 and 3 weeks after the operation. The blood samples were collected in tubes containing Na2EDTA anti-coagulant and centrifuged at 1,500 × g for 10 min. The supernatant was collected and preserved at −80°C or directly used for the detection of Ps and ET-1. Serum Ps was detected using a human Ps detection kit (cat. no. P1038; Shanghai Airui Biotechnology Co., Ltd., Shanghai, China) and serum ET-1 was detected using a human ET-1 detection kit (cat. no. E2567; Shanghai Yu Bo Biotech Co., Ltd., Shanghai, China), which were performed in triplicate.

 Statistical analysis

Data were analyzed using SPSS 19.0 software (IBM Corp., Armonk, NY, USA). The patient age and serum levels of Ps and ET-1 were expressed as the mean ± standard deviation. An independent-samples t-test was performed to determine the significance of differences between the two groups. Count data were expressed as n (%) and compared between the two groups using the Chi-squared test. The predictive value of Ps and ET-1 for restenosis was determined by generating receiver operating characteristics (ROC) curves and determining the area under the ROC curve (AUC), as well as the sensitivity and specificity at optimal cut-off values. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Comparison of pre- and post-operative CTA observations between the two groups

The position of the lesions was confirmed by CTA. The two representative cases in Fig. 1A and B had stenosis of the iliac artery and received PTA combined with stent placement. They were followed up for 1 year post-operatively. The first representative case had post-operative restenosis (Fig. 1C), while the second one had no restenosis (Fig. 1D).

 Comparison of serum Ps levels at different time-points

Compared with the pre-operative level, the level of serum Ps 1 h after the operation was significantly increased in the PAD cases (P<0.05), and then declined over time until stabilizing 2 weeks post-operatively. The serum Ps levels at 1 h, 1, 2 and 3 weeks after the operation in the restenosis group were significantly higher than those in the non-restenosis group (P<0.05). Within the restenosis group, the post-operative Ps levels were also significantly higher than the pre-operative ones (P<0.05). However, for the non-restenosis group, the serum Ps levels at 1, 2 and 3 weeks post-operatively were not significantly different from the pre-operative levels (P>0.05; Table II).

 Comparison of serum ET-1 levels at different time-points

As compared with the pre-operative level, the serum ET-1 level at 1 h after the operation was significantly increased in all PAD cases (P<0.05), and it declined afterwards until stabilizing at 2 weeks post-operatively. The serum ET-1 levels at 1 h, 1, 2 and 3 weeks post-operatively in the restenosis group, were significantly higher than those in the non-restenosis group (P<0.05). Within the restenosis group, they were also significantly higher than the pre-operative levels (P<0.05). However, in the non-restenosis group, the serum ET-1 levels at 1, 2 and 3 weeks post-operatively were not significantly different from the pre-operative levels (P>0.05; Table III).

 Predictive value of Ps and ET-1 levels for post-operative restenosis

ROC curves comparing the sensitivity vs. specificity of the serum levels of Ps or ET-1 for predicting post-operative restenosis were plotted using SPSS 19.0 software (Fig. 2). For the serum levels of Ps as well as ET-1, the AUC was >0.5 at each time-point post-operatively. The AUC increased over time, indicating a better diagnostic value of the later time-points for post-operative restenosis. However, in the clinic, earlier discovery and treatment of post-operative restenosis for PAD cases results in better the outcomes.

The optimal diagnostic threshold at 1 h post-operatively was 38.83 ng/ml for serum Ps levels, as calculated from the ROC curve. The corresponding sensitivity and specificity for predicting restenosis were 75 and 90%, respectively. The optimal diagnostic threshold at 1 h post-operatively was 0.1089 ng/ml for serum ET-1 levels, as calculated from the ROC curve. The corresponding sensitivity and specificity for predicting restenosis were 85 and 85%, respectively.

 Discussion

VECs provide a barrier between the vascular system and underlying tissues. The nitric oxide, endothelin, angiotensin and growth factors secreted by VECs mediate vascular relaxation and contraction. Arteriosclerosis may induce the secretion of heparin-like substances, smooth muscle relaxant factors and smooth muscle constricting factors by VECs, thus inhibiting the proliferation and migration of VECs (9,10). Abnormal proliferation and migration of the VECs are considered as the major reasons for post-operative restenosis for PAD patients, as they result in intimal hyperplasia and remodeling of elasticity of vascular walls (11). Interventional therapies for PAD patients may cause damage to the vascular endothelium, leading to decreased secretion of factors that inhibit the proliferation and migration of smooth muscle cells (SMCs); this in turn may cause restenosis to occur (6). In addition, damage of VECs may further promote thrombosis and vasoconstriction, leading to restenosis. Therefore, evaluating the damage of VECs in PAD patients after endovascular therapy is of high importance for predicting post-operative restenosis.

Ps is an important member of the selectin family of cell adhesion molecules (12). Under normal physiological conditions, Ps rests on the granule membrane of platelets. Once activated by VEC damage, the platelets release the platelet α granules and Ps is released along with them. Therefore, Ps is considered as an indicator of the activated state of the platelets. For PAD patients who have received interventional therapy, the activated state of the platelets may be used to assess the degree of VEC damage. Therefore, Ps is an indirect indicator of VEC damage. In the present study, the serum Ps levels were significantly increased in PAD patients at 1 h after the operation as compared with the pre-operative levels (P<0.05). Thomas et al (13) reported a significant correlation between Ps levels and the post-operative onset of cardiovascular events in acute coronary syndrome. According to Myers Jr et al (14), oral Ps inhibitor PSI-697 reduced thrombosis in rats with venous stenosis. This means that Ps levels in the blood are not only an indicator of VEC damage, but also associated with thrombosis and restenosis. Inhibiting blood Ps may help reduce restenosis in PAD cases.

In the present study, the serum Ps levels at 1 h, 1, 2 and 3 weeks post-operatively in the restenosis group were significantly higher than those in the non-restenosis group (P<0.05); they were also considerably increased as compared with the pre-operative level within the restenosis group (P<0.05). However, for the non-restenosis group, there was no significant difference in the serum Ps levels at 1 h, 1, 2 and 3 weeks post-operatively as compared with the pre-operative level (P>0.05). For the serum Ps levels, the sensitivity and specificity for predicting restenosis in PAD patients were 75 and 90%, respectively, with a cut-off at 38.85 ng/ml. Ps on the platelet α granule membrane not only promotes the expression and secretion of tissue factors by the leukocytes, thus triggering coagulation, but also recruit neutrophil granulocytes, thus aggravating VEC damage. This further promotes thrombosis and increases the risk of restenosis (15). Ps is a member of the selectin family of cell adhesion molecules. It is expressed on stimulated endothelial cells and activated platelets, and mediates leukocyte rolling on stimulated endothelial cells, as well as heterotypic aggregation of activated platelets onto leukocytes (16). The importance of Ps-mediated cell adhesive interactions in the pathogeneses of inflammation and thrombosis has been demonstrated in Ps-knockout mice (17). Therefore, the post-operative serum Ps levels in PAD cases may provide information on VEC damage and serve in the prediction of restenosis.

ET-1 is a vasoconstrictor secreted mainly by endothelial cells. It activates the Ca2+ channel of vascular SMCs by binding to receptors and then induces contraction of vascular SMCs. In the present study, a significant increase in the serum ET-1 levels was identified in PAD patients at 1 h post-operatively (P<0.05). Furthermore, the ET-1 levels at 1 h, 1, 2 and 3 weeks post-operatively in the restenosis group were significantly higher than those in the non-restenosis group (P<0.05); they were also higher than the pre-operative levels within the restenosis group (P<0.05). However, for the non-restenosis group, the serum ET-1 levels at 1 h, 1, 2 and 3 weeks post-operatively were not significantly different from the pre-operative level (P>0.05).

The reasons for the increased ET-1 secretion after endovascular therapy remain to be fully elucidated. Upregulation of ET-1 promotes the proliferation and migration of SMCs, thus leading to intimal hyperplasia and post-operative restenosis (18). According to Biasin et al (19) and Jiang et al (20) upregulation of ET-1 resulted in the proliferation of pulmonary artery SMCs. Under normal conditions, a dynamic balance between vasoconstrictive factors (e.g., ET-1) and vasodilatory factors (e.g., nitric oxide) prevails. However, upregulation of ET-1 following endovascular therapy disturbs this balance, leading to enhanced platelet adhesion, thrombosis, and abnormal proliferation and migration of SMCs (21,22). This finally results in restenosis. Therefore, the ET-1 levels after endovascular therapy may serve as a predictive marker for restenosis. Based on the present results, the sensitivity and specificity of serum ET-1 with a cut-off at 0.1089 pg/ml at 1 h after the operation for predicting restenosis were 85 and 85%, respectively.

In conclusion, the levels of serum Ps and ET-1 in PAD patients after endovascular surgery are of great clinical value for predicting post-operative vascular restenosis.

 Acknowledgements

Not applicable.

 Funding

No funding was received.

 Availability of data and materials

The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.

 Authors' contributions

NC and TL contributed to the concept and design of the study. NC and TL analyzed and interpreted the patient data. LC, SJ and ZW analyzed the data. NC, LC and TL prepared the manuscript. All authors read and approved the final manuscript.

 Ethical approval and consent to participate

All of the experiments were approved by the Ethics Committee of Nanjing University of Chinese Medicine (Nanjing, China). All patients provided written informed consent.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References AlahdabFWangATElraiyahTAMalgorRDRizviAZLaneMAProkopLJMontoriVMConteMSMuradMHA systematic review for the screening for peripheral arterial disease in asymptomatic patientsJ Vasc Surg61Suppl 3S42S53201510.1016/j.jvs.2014.12.008 CriquiMHAboyansVEpidemiology of peripheral artery diseaseCirc Res11615091526201510.1161/CIRCRESAHA.116.30384925908725 LinTYYangFCLinCLKaoCHLoHYYangTYHerpes zoster infection increases the risk of peripheral arterial disease: A nationwide cohort studyMedicine (Baltimore)95e4480201610.1097/MD.000000000000403727583856 BaerlocherMOKennedySARajebiMRBaerlocherFJMisraSLiuDNikolicBMeta-analysis of drug-eluting balloon angioplasty and drug-eluting stent placement for infrainguinal peripheral arterial diseaseJ Vasc Interv Radiol26459473201510.1016/j.jvir.2014.12.01325703839 KumadaYAoyamaTIshiiHTanakaMKawamuraYTakahashiHToriyamaTAoyamaTYuzawaYMaruyamaSLong-term outcome of percutaneous transluminal angioplasty in chronic haemodialysis patients with peripheral arterial diseaseNephrol Dial Transplant2339964001200810.1093/ndt/gfn37818596131 KoskinasKCChatzizisisYSAntoniadisAPGiannoglouGDRole of endothelial shear stress in stent restenosis and thrombosis: Pathophysiologic mechanisms and implications for clinical translationJ Am Coll Cardiol5913371349201210.1016/j.jacc.2011.10.90322480478 WilsonWRFitridgeRAWeekesAJMorganCTavellaRBeltrameJFQuality of life of patients with peripheral arterial disease and chronic stable anginaAngiology63223228201210.1177/000331971141311921733948 KumakuraHKanaiHArakiYHojoYIwasakiTIchikawaS15-year patency and life expectancy after primary stenting guided by intravascular ultrasound for iliac artery lesions in peripheral arterial diseaseJACC Cardiovasc Interv818931901201510.1016/j.jcin.2015.08.02026604061 KutlarAAtagaKIMcMahonLHowardJGalacterosFHagarWVichinskyECheungATMatsuiNEmburySHA potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell diseaseAm J Hematol87536539201210.1002/ajh.2314722488107 AbrahamDDistlerOHow does endothelial cell injury start? The role of endothelin in systemic sclerosisArthritis Res Ther9Suppl 2S2200710.1186/ar210617767740 MichelJBLiZLacolleyPSmooth muscle cells and vascular diseasesCardiovasc Res95135137201210.1093/cvr/cvs17222637748 GuPTheissAHanJFeaginsLAIncreased cell adhesion molecules, PECAM-1, ICAM-3, or VCAM-1, predict increased risk for flare in patients with quiescent inflammatory bowel diseaseJ Clin Gastroenterol51522527201710.1097/MCG.000000000000061827552332 ThomasMRWijeyeratneYDMayJAJohnsonAHeptinstallSFoxSCA platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrelPlatelets25612618201410.3109/09537104.2013.86385824433232 MyersDDJrHenkePKBedardPWWrobleskiSKKailaNShawGMeierTRHawleyAESchaubRGWakefieldTWTreatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosisJ Vasc Surg44625632200610.1016/j.jvs.2006.05.02116950445 PabingerIAyCBiomarkers and venous thromboembolismArterioscler Thromb Vasc Biol29332336200910.1161/ATVBAHA.108.18218819228607 GengJGChenMChouKCP-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasisCurr Med Chem1121532160200410.2174/092986704336472015279555 PanickerSRMehta-D'souzaPZhangNKlopockiAGShaoBMceverRPCirculating soluble P-selectin must dimerize to promote inflammation and coagulation in miceBlood130181191201710.1182/blood-2017-02-77047928515093 PabingerIAyCBiomarkers and venous thromboembolismArterioscler Thromb Vasc Biol29332336200910.1161/ATVBAHA.108.18218819228607 BiasinVChwalekKWilhelmJBestJMarshLMGhanimBKlepetkoWFinkLSchermulyRTWeissmannNEndothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependentInt J Biochem Cell Biol54137148201410.1016/j.biocel.2014.06.02025016214 JiangHNZengBChenGLLaiBLuSHQuJMLipopolysaccharide potentiates endothelin-1-induced proliferation of pulmonary arterial smooth muscle cells by upregulating TRPC channelsBiomed Pharmacother822027201610.1016/j.biopha.2016.04.05527470334 MeoliDFWhiteRJEndothelin-1 induces pulmonary but not aortic smooth muscle cell migration by activating ERK1/2 MAP kinaseCan J Physiol Pharmacol88830839201010.1139/Y10-05920725141 RomanoFGambaraGDe CesarisPZiparoEPalombiFFilippiniAEndothelin induces functional hypertrophy of peritubular smooth muscle cellsJ Cell Physiol212264273200710.1002/jcp.2102817311294

Representative pre- and post-operative CTA images for the two groups. (A) Right stenosis indicated by pre-operative CTA in the restenosis group and (B) right restenosis indicated by post-operative CTA in the restenosis group from a 54-year-old male patient. (C) Left stenosis indicated by pre-operative CTA in the non-restenosis group and (D) no restenosis on the left indicated by post-operative CTA in the non-restenosis group from a 52-year-old male patient. The site of (previous) (re)stenosis is indicated by arrows. CTA, computed tomography-angiography.

Receiver operating characteristic curves for assessing the utility of serum Ps and ET-1 levels determined at different post-operative time-points in diagnosing restenosis. Ps, P-selectin; ET-1, endothelin-1.

Comparison of the demographic and clinicopathological characteristics of the patients in the restenosis vs. non-restenosis group (n=20 per group).

Characteristics Restenosis group Non-restenosis group t/χ2 P-value
Average age, years 63.20±6.39 62.70±6.18 0.252 0.803
Male, n (%) 12 (60) 11 (55) 0.102 0.794
Comorbidities
  Hypertension, n (%) 18 (90) 19 (95) 0.360 0.548
  Hyperlipidemia, n (%) 16 (80) 13 (65) 1.129 0.288
Family history of PAD, n (%) 15 (75) 13 (65) 0.476 0.490
Smoking, n (%) 12 (60) 8 (40) 1.600 0.206
Rutherford stage, n (%) 0.702 0.873
  III 3 (15) 5 (25)
  IV 9 (45) 8 (40)
  V 4 (20) 4 (20)
  VI 4 (20) 3 (15)
Lesion site, n (%) 0.567 0.904
  Unilateral iliac artery 6 (30) 5 (25)
  Simple superficial femoral artery 5 (25) 7 (35)
  Ipsilateral iliac and femoral artery 5 (25) 5 (25)
  Femoral popliteal artery 4 (20) 3 (15)

Values are expressed as the mean ± standard deviation or n (%).

Comparison of serum P-selectin levels at different time-points (ng/ml).

Groups/time Restenosis group (n=20) Non-restenosis group (n=20) t P-value
Pre-operative 20.54±2.40 20.97±2.13   0.594   0.556
Post-operative
  1 h 41.67±3.89a 34.82±3.16a   6.123 <0.001
  1 week 34.19±3.76a 22.63±3.69   9.817 <0.001
  2 weeks 32.15±2.56a 19.95±2.05 16.616 <0.001
  3 weeks 32.00±2.77a 19.88±1.76 16.504 <0.001

P<0.05, compared with the pre-operative level for the same group.

Comparison of serum endothelin-1 levels (pg/ml) at different time-points.

Groups/time Restenosis group (n=20) Non-restenosis group (n=20) t P-value
Pre-operative 75.29±3.62 75.16±3.56 0.110 0.913
Post-operative
1 h 114.21±4.60a 101.97±5.18a 7.901 <0.001
1 week 98.58±5.16a 80.66±5.46 10.664 <0.001
2 weeks 97.95±5.88a 77.39±4.79 12.114 <0.001
3 weeks 97.71±5.34a 77.04±3.34 14.680 <0.001

P<0.05, compared with the pre-operative level for the same group.